---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-171994"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2022-06-10T23:59:59+00:00"
generated_at: "2026-06-25T02:46:08.893997+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines increases CEO Mark Goldsmith's change-in-control severance to 2x salary plus bonus

## Summary
- Severance multiplier raised from 1.5x to 2x for CEO Mark Goldsmith upon qualifying termination near a change in control.
- Applies to termination without cause or resignation for good reason from 3 months before to 18 months after a change in control.
- Amendment approved by Compensation Committee on June 8, 2022, and executed on June 10, 2022.
- Lump sum cash payment equals 2x annual base salary plus target annual bonus.
- No other terms of the employment agreement were changed.

## SEC filing metadata
- accession: 0001193125-22-171994
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2022-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312522171994/0001193125-22-171994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312522171994/d331499d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-171994
- JSON: https://secwatch.observer/filing/0001193125-22-171994.json
- Plain text: https://secwatch.observer/filing/0001193125-22-171994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.